Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors. Correlations between somatic mutations and first-line targeted therapy outcomes have not been reported on a randomize...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol
Main Authors: Hsieh, James J., Chen, David, Wang, Patricia I., Marker, Mahtab, Redzematovic, Almedina, Chen, Ying-Bei, Selcuklu, S. Duygu, Weinhold, Nils, Bouvier, Nancy, Huberman, Kety H., Bhanot, Umesh, Chevinsky, Michael S., Patel, Parul, Pinciroli, Patrizia, Won, Helen H., You, Daoqi, Viale, Agnes, Lee, William, Hakimi, A. Ari, Berger, Michael F., Socci, Nicholas D., Cheng, Emily H., Knox, Jennifer, Voss, Martin H., Voi, Maurizio, Motzer, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431298/
https://ncbi.nlm.nih.gov/pubmed/27751729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.10.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados